BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30592984)

  • 1. Understanding relaxin signalling at the cellular level.
    Valkovic AL; Bathgate RA; Samuel CS; Kocan M
    Mol Cell Endocrinol; 2019 May; 487():24-33. PubMed ID: 30592984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.
    Chow BS; Chew EG; Zhao C; Bathgate RA; Hewitson TD; Samuel CS
    PLoS One; 2012; 7(8):e42714. PubMed ID: 22936987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relaxin family peptide receptors--former orphans reunite with their parent ligands to activate multiple signalling pathways.
    Halls ML; van der Westhuizen ET; Bathgate RA; Summers RJ
    Br J Pharmacol; 2007 Mar; 150(6):677-91. PubMed ID: 17293890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-fibrotic actions of relaxin are mediated through AT
    Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
    FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging roles for the relaxin/RXFP1 system in cancer therapy.
    Thanasupawat T; Glogowska A; Nivedita-Krishnan S; Wilson B; Klonisch T; Hombach-Klonisch S
    Mol Cell Endocrinol; 2019 May; 487():85-93. PubMed ID: 30763603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The different ligand-binding modes of relaxin family peptide receptors RXFP1 and RXFP2.
    Scott DJ; Rosengren KJ; Bathgate RA
    Mol Endocrinol; 2012 Nov; 26(11):1896-906. PubMed ID: 22973049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, beta-arrestin 2, PDE4D3 complex.
    Halls ML; Cooper DM
    EMBO J; 2010 Aug; 29(16):2772-87. PubMed ID: 20664520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relaxin receptor as a therapeutic target - perspectives from evolution and drug targeting.
    Bathgate RAD; Kocan M; Scott DJ; Hossain MA; Good SV; Yegorov S; Bogerd J; Gooley PR
    Pharmacol Ther; 2018 Jul; 187():114-132. PubMed ID: 29458108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relaxin signaling activates peroxisome proliferator-activated receptor gamma.
    Singh S; Bennett RG
    Mol Cell Endocrinol; 2010 Feb; 315(1-2):239-45. PubMed ID: 19712722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.
    Chen TY; Li X; Hung CH; Bahudhanapati H; Tan J; Kass DJ; Zhang Y
    Mol Genet Genomic Med; 2020 Apr; 8(4):e1194. PubMed ID: 32100955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1.
    Hossain MA; Kocan M; Yao ST; Royce SG; Nair VB; Siwek C; Patil NA; Harrison IP; Rosengren KJ; Selemidis S; Summers RJ; Wade JD; Bathgate RAD; Samuel CS
    Chem Sci; 2016 Jun; 7(6):3805-3819. PubMed ID: 30155023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time examination of cAMP activity at relaxin family peptide receptors using a BRET-based biosensor.
    Valkovic AL; Leckey MB; Whitehead AR; Hossain MA; Inoue A; Kocan M; Bathgate RAD
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00432. PubMed ID: 30263124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural commonality of C1q TNF-related proteins and their potential to activate relaxin/insulin-like family peptide receptor 1 signalling pathways in cancer cells.
    Klonisch T; Glogowska A; Thanasupawat T; Burg M; Krcek J; Pitz M; Jaggupilli A; Chelikani P; Wong GW; Hombach-Klonisch S
    Br J Pharmacol; 2017 May; 174(10):1025-1033. PubMed ID: 27443788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.
    Kocan M; Sarwar M; Ang SY; Xiao J; Marugan JJ; Hossain MA; Wang C; Hutchinson DS; Samuel CS; Agoulnik AI; Bathgate RAD; Summers RJ
    Sci Rep; 2017 Jun; 7(1):2968. PubMed ID: 28592882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective actions of relaxin.
    Martin B; Romero G; Salama G
    Mol Cell Endocrinol; 2019 May; 487():45-53. PubMed ID: 30625345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.
    Halls ML; Bathgate RA; Sutton SW; Dschietzig TB; Summers RJ
    Pharmacol Rev; 2015; 67(2):389-440. PubMed ID: 25761609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of the receptor, the ligand, and the cell in the signal transduction pathways utilized by the relaxin family peptide receptors 1-3.
    Summers RJ; Bathgate RA; Wade JD; van der Westhuizen ET; Halls ML
    Ann N Y Acad Sci; 2009 Apr; 1160():99-104. PubMed ID: 19416167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relaxin family peptides and their receptors.
    Bathgate RA; Halls ML; van der Westhuizen ET; Callander GE; Kocan M; Summers RJ
    Physiol Rev; 2013 Jan; 93(1):405-80. PubMed ID: 23303914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptors for relaxin family peptides.
    Bathgate RA; Ivell R; Sanborn BM; Sherwood OD; Summers RJ
    Ann N Y Acad Sci; 2005 May; 1041():61-76. PubMed ID: 15956688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
    Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
    Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.